

# Damian F J Purcell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4542927/publications.pdf>

Version: 2024-02-01

62  
papers

1,813  
citations

304368

22  
h-index

315357

38  
g-index

70  
all docs

70  
docs citations

70  
times ranked

3204  
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein(CD46) and decay accelerating factor (CD55). <i>European Journal of Immunology</i> , 1992, 22, 1579-1585.	1.6	142
2	Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	109
3	Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. <i>Retrovirology</i> , 2007, 4, 89.	0.9	82
4	Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. <i>Retrovirology</i> , 2011, 8, 80.	0.9	82
5	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1383-1394.	4.6	82
6	SARS-CoV-2 suppresses IFN $\beta$ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. <i>PLoS Pathogens</i> , 2021, 17, e1009800.	2.1	74
7	A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. <i>Aids</i> , 2006, 20, 294-297.	1.0	58
8	Small Interfering RNAs against the TAR RNA Binding Protein, TRBP, a Dicer Cofactor, Inhibit Human Immunodeficiency Virus Type 1 Long Terminal Repeat Expression and Viral Production. <i>Journal of Virology</i> , 2007, 81, 5121-5131.	1.5	58
9	Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting. <i>Journal of Infectious Diseases</i> , 2020, 222, 1280-1288.	1.9	56
10	Hyperimmune Bovine Colostrum as a Low-Cost, Large-Scale Source of Antibodies with Broad Neutralizing Activity for HIV-1 Envelope with Potential Use in Microbicides. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4310-4319.	1.4	50
11	Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN $\gamma$ or IL-12. <i>Vaccine</i> , 2004, 23, 188-197.	1.7	47
12	Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. <i>Virology</i> , 2008, 379, 125-134.	1.1	45
13	Genetic and Functional Analysis of R5X4 Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Derived from Two Individuals Homozygous for the CCR5 $\Delta$ 32 Allele. <i>Journal of Virology</i> , 2006, 80, 3684-3691.	1.5	43
14	The Molecular Biology of HIV Latency. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 187-212.	0.8	43
15	Infrared Based Saliva Screening Test for COVID-19. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 17102-17107.	7.2	42
16	Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. <i>Vaccine</i> , 2009, 27, 6605-6612.	1.7	38
17	Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance. <i>Nature Communications</i> , 2021, 12, 4270.	5.8	37
18	Selectively Reduced tat mRNA Heralds the Decline in Productive Human Immunodeficiency Virus Type 1 Infection in Monocyte-Derived Macrophages. <i>Journal of Virology</i> , 2002, 76, 12611-12621.	1.5	34

#	ARTICLE	IF	CITATIONS
19	Both Linear and Discontinuous Ribosome Scanning Are Used for Translation Initiation from Bicistronic Human Immunodeficiency Virus Type 1 env mRNAs. <i>Journal of Virology</i> , 2007, 81, 4664-4676.	1.5	33
20	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. <i>JCI Insight</i> , 2021, 6, .	2.3	33
21	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. <i>EBioMedicine</i> , 2021, 74, 103729.	2.7	29
22	Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e2-e10.	4.6	28
23	HIV latency reversing agents act through Tat post translational modifications. <i>Retrovirology</i> , 2018, 15, 36.	0.9	24
24	Gene expression signatures of circulating human type 1, 2, and 3 innate lymphoid cells. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2321-2325.	1.5	24
25	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. <i>EBioMedicine</i> , 2021, 65, 103241.	2.7	24
26	Efficient transcription through an intron requires the binding of an Sm-type U1 snRNP with intact stem loop II to the splice donor. <i>Nucleic Acids Research</i> , 2010, 38, 3041-3053.	6.5	23
27	Identification of Native and Posttranslationally Modified HLA-B*57:01-Restricted HIV Envelope Derived Epitopes Using Immunoproteomics. <i>Proteomics</i> , 2018, 18, e1700253.	1.3	23
28	Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab239.	0.4	23
29	Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. <i>European Journal of Immunology</i> , 2012, 42, 2771-2781.	1.6	22
30	Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression. <i>Retrovirology</i> , 2008, 5, 28.	0.9	21
31	Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection. <i>Virology</i> , 2010, 396, 246-255.	1.1	20
32	HIV-1-Based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions. <i>Viruses</i> , 2019, 11, 507.	1.5	17
33	Co-Expression of miRNA Targeting the Expression of PERK, but Not PKR, Enhances Cellular Immunity from an HIV-1 Env DNA Vaccine. <i>PLoS ONE</i> , 2011, 6, e18225.	1.1	16
34	Multiplex Droplet Digital PCR Assay for Quantification of Human T-Cell Leukemia Virus Type 1 Subtype c DNA Proviral Load and T Cells from Blood and Respiratory Exudates Sampled in a Remote Setting. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	15
35	Optimal preparation of SARS-CoV-2 viral transport medium for culture. <i>Virology Journal</i> , 2021, 18, 53.	1.4	15
36	Infrared Based Saliva Screening Test for COVID-19. <i>Angewandte Chemie</i> , 2021, 133, 17239-17244.	1.6	15

#	ARTICLE	IF	CITATIONS
37	Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 835.	1.8	15
38	p30 protein: a critical regulator of HTLV-1 viral latency and host immunity. <i>Retrovirology</i> , 2019, 16, 42.	0.9	13
39	Role of HTLV-1 orf-I encoded proteins in viral transmission and persistence. <i>Retrovirology</i> , 2019, 16, 43.	0.9	13
40	Impact of Hepatitis B Virus Coinfection on Human T-Lymphotropic Virus Type 1 Clonality in an Indigenous Population of Central Australia. <i>Journal of Infectious Diseases</i> , 2019, 219, 562-567.	1.9	13
41	Tat IRES modulator of tat mRNA (TIM-TAM): a conserved RNA structure that controls Tat expression and acts as a switch for HIV productive and latent infection. <i>Nucleic Acids Research</i> , 2020, 48, 2643-2660.	6.5	13
42	Water-Borne Nanocoating for Rapid Inactivation of SARS-CoV-2 and Other Viruses. <i>ACS Nano</i> , 2021, 15, 14915-14927.	7.3	13
43	MYB Elongation Is Regulated by the Nucleic Acid Binding of NF $\kappa$ B p50 to the Intronic Stem-Loop Region. <i>PLoS ONE</i> , 2015, 10, e0122919.	1.1	12
44	Evaluation of virucidal activity of residual quaternary ammonium-treated surfaces on SARS-CoV-2. <i>American Journal of Infection Control</i> , 2022, 50, 325-329.	1.1	11
45	Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response. <i>PLoS ONE</i> , 2016, 11, e0157353.	1.1	10
46	Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env. <i>MAbs</i> , 2017, 9, 550-566.	2.6	8
47	Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env. <i>Vaccines</i> , 2021, 9, 239.	2.1	8
48	The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency. <i>Frontiers in Genetics</i> , 2021, 12, 680725.	1.1	7
49	Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2021, 95, e0021921.	1.5	7
50	Application of a case-control study design to investigate genotypic signatures of HIV-1 transmission. <i>Retrovirology</i> , 2012, 9, 54.	0.9	5
51	Functional properties and sequence variation of HTLV-1 p13. <i>Retrovirology</i> , 2020, 17, 11.	0.9	5
52	The Efficacy of Common Household Cleaning Agents for SARS-CoV-2 Infection Control. <i>Viruses</i> , 2022, 14, 715.	1.5	5
53	Suppression subtractive hybridization method for the identification of a new strain of murine hepatitis virus from xenografted SCID mice. <i>Archives of Virology</i> , 2015, 160, 2945-2955.	0.9	3
54	Differentiating founder and chronic HIV envelope sequences. <i>PLoS ONE</i> , 2017, 12, e0171572.	1.1	3

#	ARTICLE	IF	CITATIONS
55	Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 855290.	1.8	3
56	Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. <i>Cell Reports Medicine</i> , 2022, 3, 100635.	3.3	3
57	Comment on Ultrarapid On-Site Detection of SARS-CoV-2 Infection Using Simple ATR-FTIR Spectroscopy and an Analysis Algorithm: High Sensitivity and Specificity. <i>Analytical Chemistry</i> , 2021, 93, 16974-16976.	3.2	2
58	Liquid Chalk Is an Antiseptic against SARS-CoV-2 and Influenza A Respiratory Viruses. <i>MSphere</i> , 2021, 6, e0031321.	1.3	1
59	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
60	Chimeric Bovine-V-region and Human-C-region mAbs with Long and Extensively Mutated CDHR3 Domains Bind HIV-1 Env gp140 Trimers, but Not gp120 Monomer. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A121-A122.	0.5	0
61	Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting. <i>PLoS ONE</i> , 2019, 14, e0220986.	1.1	0
62	High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	0